GlobeImmune, Inc., today announced that initial survival data from GI-4000-02, a Phase 2b study of the company’s lead cancer product candidate, GI-4000, in subjects with resected pancreas cancer, have been accepted for oral presentation at the European Society for Medical … Continue reading
Survival Data from GlobeImmune’s Phase 2b Study in Patients with Resected Pancreas Cancer to be Presented at ESMO 14th World Congress on Gastrointestinal Cancer
May 31, 2012